Movement Alert｜Merck Falls 3.13% in Regular Trading, Selling Pressure Prevails Despite Target Price Upgrades

Market Focus10-05

On October 5, Merck fell 3.13% in regular trading at $139.75. The decline occurred despite JP Morgan, Jefferies, and Scotiabank raising their target prices to $165, $177, and $180 respectively on the same day, with selling pressure dominating market sentiment.

Market participants may be taking profits after a recent series of positive catalysts, including clinical trial results for diabetes and hidradenitis suppurativa treatments, new drug approvals, and collaborations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment